Ray D. Page

4.0k total citations · 1 hit paper
80 papers, 2.0k citations indexed

About

Ray D. Page is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Ray D. Page has authored 80 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 17 papers in Economics and Econometrics. Recurrent topics in Ray D. Page's work include Lung Cancer Treatments and Mutations (27 papers), Economic and Financial Impacts of Cancer (17 papers) and Cancer Treatment and Pharmacology (11 papers). Ray D. Page is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Economic and Financial Impacts of Cancer (17 papers) and Cancer Treatment and Pharmacology (11 papers). Ray D. Page collaborates with scholars based in United States, Canada and France. Ray D. Page's co-authors include Stephen G. Divers, Richard B. Lanman, Davey B. Daniel, Daniel Dix, Justin I. Odegaard, Karen L. Reckamp, Victoria M. Raymond, Natasha B. Leighl, Miguel A. Villalona‐Calero and Vassiliki A. Papadimitrakopoulou and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Ray D. Page

76 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

2019 408 citations Natasha B. Leighl, Ray D. Page et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ray D. Page United States	23	976	839	561	434	290	80	2.0k
Maysa Abu‐Khalaf United States	23	986 1.0×	312 0.4×	614 1.1×	350 0.8×	328 1.1×	91	1.8k
Patricia M. Jamison United States	13	1.4k 1.4×	505 0.6×	397 0.7×	410 0.9×	150 0.5×	19	2.5k
Maria Carmela Piccirillo Italy	26	1.2k 1.3×	787 0.9×	408 0.7×	502 1.2×	156 0.5×	94	2.3k
Gilberto Lopes United States	21	1.2k 1.2×	874 1.0×	284 0.5×	259 0.6×	156 0.5×	108	1.9k
Lucìa Mangone Italy	22	1.3k 1.3×	484 0.6×	373 0.7×	345 0.8×	112 0.4×	96	2.1k
Norbert Marschner Germany	25	1.3k 1.3×	649 0.8×	349 0.6×	407 0.9×	90 0.3×	153	2.2k
Sidney Scudder United States	20	603 0.6×	316 0.4×	286 0.5×	406 0.9×	246 0.8×	49	1.9k
Paul Smith United Kingdom	26	1.2k 1.2×	257 0.3×	534 1.0×	534 1.2×	132 0.5×	65	2.6k
Daniel M. Geynisman United States	30	877 0.9×	848 1.0×	359 0.6×	630 1.5×	379 1.3×	174	2.5k
Carol Townsley Canada	15	674 0.7×	397 0.5×	174 0.3×	245 0.6×	242 0.8×	35	1.4k

Countries citing papers authored by Ray D. Page

Since Specialization

Citations

This map shows the geographic impact of Ray D. Page's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray D. Page with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray D. Page more than expected).

Fields of papers citing papers by Ray D. Page

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray D. Page. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray D. Page. The network helps show where Ray D. Page may publish in the future.

Co-authorship network of co-authors of Ray D. Page

This figure shows the co-authorship network connecting the top 25 collaborators of Ray D. Page. A scholar is included among the top collaborators of Ray D. Page based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ray D. Page. Ray D. Page is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schenkel, Caroline, Laura A. Levit, M. Kelsey Kirkwood, et al.. (2025). State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023. PubMed. 2(2). e2400010–e2400010. 4 indexed citations

Kim, Jong Hoon, et al.. (2023). Exceedingly Rare Bilateral Synchronous Germ Cell Testicular Tumors With Different Histopathological Features. Cureus. 15(7). e42374–e42374. 1 indexed citations

Gajra, Ajeet, et al.. (2023). Reducing Avoidable Emergency Visits and Hospitalizations With Patient Risk-Based Prescriptive Analytics: A Quality Improvement Project at an Oncology Care Model Practice. JCO Oncology Practice. 19(5). e725–e731. 6 indexed citations

Schenkel, Caroline, Laura A. Levit, Rebecca Spence, et al.. (2023). The state of workforce retention among US oncologists.. JCO Oncology Practice. 19(11_suppl). 42–42. 1 indexed citations

Zoň, Robin, Erin B. Kennedy, Kerin B. Adelson, et al.. (2021). Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice. 17(9). 546–564. 92 indexed citations

Page, Ray D., et al.. (2021). Guidance on Implementing an Oral Chemotherapy Drug Repository Program in a Medically Integrated Pharmacy Setting. JCO Oncology Practice. 17(7). e448–e453. 1 indexed citations

Hlubocky, Fay J., Anthony L. Back, Tait D. Shanafelt, et al.. (2021). Occupational and Personal Consequences of the COVID-19 Pandemic on US Oncologist Burnout and Well-Being: A Study From the ASCO Clinician Well-Being Task Force. JCO Oncology Practice. 17(7). e427–e438. 28 indexed citations

Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 72–81. 31 indexed citations

Page, Ray D., et al.. (2020). Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment. Journal of the American Pharmacists Association. 61(1). 53–59. 9 indexed citations

10.

Page, Ray D., et al.. (2020). Factors associated with adherence to follow-up calls in cancer patients receiving care at a community oncology practice. Journal of Oncology Pharmacy Practice. 27(5). 1094–1101. 3 indexed citations

11.

McFarlane, Joshua J., Mark D. Kochenderfer, Mark R. Olsen, et al.. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer. 18(6). 469–476.e4. 29 indexed citations

12.

Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, et al.. (2019). Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clinical Cancer Research. 25(15). 4691–4700. 408 indexed citations breakdown →

13.

Knox, Jennifer J., Carlos H. Barrios, T.M. Kim, et al.. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology. 28(6). 1339–1345. 84 indexed citations

14.

Socinski, Mark A., Isamu Okamoto, Jeremy K. Hon, et al.. (2013). Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Annals of Oncology. 24(9). 2390–2396. 57 indexed citations

15.

Socinski, Mark A., Corey J. Langer, Isamu Okamoto, et al.. (2012). Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Annals of Oncology. 24(2). 314–321. 92 indexed citations

16.

Page, Ray D., et al.. (2005). Dose‐dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma. Cancer. 104(9). 1956–1961. 10 indexed citations

17.

Page, Ray D., et al.. (2004). Pernicious Anemia: Presentations Mimicking Acute Leukemia. Southern Medical Journal. 97(3). 295–297. 19 indexed citations

18.

Hoover, R G, Christine W. Lary, Ray D. Page, et al.. (1995). Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.. Journal of Clinical Investigation. 95(1). 241–247. 22 indexed citations

19.

Page, Ray D. & Thomas Yorio. (1990). Prostaglandin F2 alpha inhibits acidification in H(+)-secreting epithelia.. Journal of Pharmacology and Experimental Therapeutics. 252(3). 929–933. 1 indexed citations

20.

Page, Ray D., Robert E. Matus, Connie E. Leifer, & Andrew S. Loar. (1985). Cisplatin, a new antineoplastic drug in veterinary medicine. Journal of the American Veterinary Medical Association. 186(3). 288–290. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact